LOS ANGELES, Oct. 20, 2025 /PRNewswire/ -- XPPen today unveiled the groundbreaking Artist 12 3rd, a new dial shortcut portable display…
ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data…
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12…
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face inflation, falling interest rates, and economic uncertainty, investors…
London, UK, Oct. 19, 2025 (GLOBE NEWSWIRE) -- As global markets face inflation, currency depreciation, and rising uncertainty, investors are…
Small cell lung cancer (SCLC) accounts for 15% of all lung cancers and remains an aggressive disease with median survival…
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100…
TOKYO, Oct. 16, 2025 /PRNewswire/ -- ESR, an Asia-Pacific ("APAC") focused real asset owner and manager, and Colt Data Centre…
GUANGZHOU, China, Oct. 16, 2025 /PRNewswire/ -- News report from GDToday: In Fiji, the Chinese language is surging in popularity.…
Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment…